{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:14:48Z","timestamp":1790234088566,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T00:00:00Z","timestamp":1385769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2014,2]]},"abstract":"\n Background and purpose<\/jats:title>\n \n Progressive multifocal leukoencephalopathy (\n PML<\/jats:styled-content>\n ) is caused by reactivation of JC virus (\n JCV<\/jats:styled-content>\n ) infection due to combined host and viral factors. Anti\u2010\n JCV<\/jats:styled-content>\n antibodies provide a means to assess\n JCV<\/jats:styled-content>\n exposure and stratify\n PML<\/jats:styled-content>\n risk. The reported seroprevalence of anti\u2010\n JCV<\/jats:styled-content>\n antibodies varies from 39% to 91% depending on assay methodology and population studied. A two\u2010step anti\u2010\n JCV<\/jats:styled-content>\n antibody assay (STRATIFY JCV\u2122; Focus Diagnostics, Cypress, CA, USA) detected anti\u2010\n JCV<\/jats:styled-content>\n antibodies in approximately 55% of multiple sclerosis (\n MS<\/jats:styled-content>\n ) patients. This study describes the prevalence of anti\u2010\n JCV<\/jats:styled-content>\n antibodies in a large, multinational\n MS<\/jats:styled-content>\n population.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This cross\u2010sectional epidemiology study was designed to enroll a minimum of 2000 patients with an\n MS<\/jats:styled-content>\n diagnosis of any type, irrespective of treatment, from Europe, Canada and Australia. Anti\u2010\n JCV<\/jats:styled-content>\n antibody prevalence was determined by\n STRATIFY JCV<\/jats:styled-content>\n ; the effects of demographic and disease characteristics were evaluated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 7724 patients from 10 countries participated in the study. Overall anti\u2010\n JCV<\/jats:styled-content>\n antibody prevalence was 57.1% (95% confidence interval 56.0%\u201358.2%). Seroprevalence was significantly associated with increasing age, gender and country of current residence (\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001). No significant differences in anti\u2010\n JCV<\/jats:styled-content>\n antibody prevalence were associated with\n MS<\/jats:styled-content>\n disease characteristics, including duration and type of\n MS<\/jats:styled-content>\n and number and duration of\n MS<\/jats:styled-content>\n therapies.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Overall seroprevalence of anti\u2010\n JCV<\/jats:styled-content>\n antibodies in\n MS<\/jats:styled-content>\n patients from Europe, Canada and Australia was consistent with previous studies using the\n STRATIFY JCV<\/jats:styled-content>\n assay. Anti\u2010\n JCV<\/jats:styled-content>\n prevalence differed significantly by age, gender and country, but no geographical pattern was evident. Disease and treatment type were not associated with differences in anti\u2010\n JCV<\/jats:styled-content>\n antibody status.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ene.12304","type":"journal-article","created":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T15:13:44Z","timestamp":1385824424000},"page":"299-304","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Anti\u2010\n JC<\/scp>\n virus (\n JCV<\/scp>\n ) antibody prevalence in the\n JCV<\/scp>\n Epidemiology in\n MS<\/scp>\n (\n JEMS<\/scp>\n ) trial"],"prefix":"10.1111","volume":"21","author":[{"given":"C.","family":"Bozic","sequence":"first","affiliation":[{"name":"Biogen Idec Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Subramanyam","sequence":"additional","affiliation":[{"name":"Biogen Idec Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Richman","sequence":"additional","affiliation":[{"name":"Biogen Idec Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Plavina","sequence":"additional","affiliation":[{"name":"Biogen Idec Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Biogen Idec Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ticho","sequence":"additional","affiliation":[{"name":"Biogen Idec Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.080708.082655"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05031-11"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10450"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/597126"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000363"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.020115-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21710"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22128"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_2_7_12_1","unstructured":"Biogen Idec Inc.Medical information website.https:\/\/medinfo.biogenidec.com\/medinfo(accessed 01\/11\/2013)."},{"key":"e_1_2_7_13_1","first-page":"S38","article-title":"Factors associated with anti\u2010JCV antibody prevalence in a large cohort of natalizumab\u2010treated MS patients","volume":"16","author":"Subramanyam M","year":"2010","journal-title":"Mult Scler"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22606"},{"issue":"4","key":"e_1_2_7_15_1","first-page":"A375","article-title":"Prevalence of anti\u2010JCV antibodies in a cohort of natalizumab\u2010treated multiple sclerosis patients from Italy","volume":"76","author":"Moiola L","year":"2011","journal-title":"Neurology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S41.002"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511429955"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.1.105-109.2000"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004565"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr012"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.12304","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.12304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:46:25Z","timestamp":1696311985000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.12304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/ene.12304"],"URL":"https:\/\/doi.org\/10.1111\/ene.12304","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,30]]},"assertion":[{"value":"2013-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}